Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | SRC | P12931 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | PDE9A | O76083 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6532758 | 0.84 | HTT (0.51) | HTTMAPTKIF11CYP3A4ALDH1A1 | |
| SCHEMBL9285803 | 0.82 | KDM4E (0.54) | DRD2DRD4DRD3HTTEGFR | |
| Water SCHEMBL11540986 | 0.79 | HTT (0.53) | DRD2HTTEGFRSRCHTR2A | |
| SCHEMBL24243783 | 0.78 | HTR2A (0.69) | DRD2DRD4DRD3HTTEGFR | |
| SCHEMBL3680016 | 0.77 | AHR (0.55) | DRD2DRD4DRD3HTTEGFR | |
| SCHEMBL24243724 | 0.77 | HTR2A (0.57) | DRD2DRD4DRD3EGFRHTR2A | |
| SCHEMBL6882102 | 0.76 | HTT (0.55) | DRD2HTTHTR2AHTR2CMAPT | |
| SCHEMBL16297142 | 0.75 | DRD2 (0.46) | DRD2DRD4DRD3HTTEGFR | |
| SCHEMBL31167422 | 0.75 | DRD2 (0.46) | DRD2DRD4DRD3HTTEGFR | |
| SCHEMBL13246948 | 0.75 | EGFR (0.64) | DRD2DRD4DRD3EGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100183658-A1 | Novel Compounds for Enhancing MHC Class II Therapies | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100183658-A1 | Novel Compounds for Enhancing MHC Class II Therapies | HLA-DRB1, CD74, MICA | DRD2 2548/4885DRD4 897/4885DRD3 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.